Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986497
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Administration
- Intravenous
01
Overview
BMS-986497 (formerly ORM-6151) is an investigational anti-CD33 antibody neoDegrader conjugate (AnDC) developed for the treatment of relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The drug consists of an antibody that specifically targets CD33-expressing tumor cells and delivers a molecular glue degrader payload that induces degradation of the peptide-chain-release factor 3 protein GSPT1 within cancer cells. This targeted degradation leads to apoptosis in both dividing and non-dividing malignant cells, offering a novel mechanism distinct from traditional DNA-damaging chemotherapies. The drug is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, efficacy, and recommended dosing in adults with relapsed or refractory AML or MDS[2][4][6].
- Other names
- anti-CD33 GSPT1 degrader BMS-986497anti-CD-33 GSPT1 degrader BMS-986497anti-CD 33 GSPT1 degrader BMS-986497
02
Targets
CD33 (Myeloid cell surface antigen CD33)CRBN (Cereblon)GSPT1 (G1 to S phase transition 1)
Beyond the preview
Go deeper on BMS-986497.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986497.